Mikael Dolsten - Nov 7, 2022 Form 4 Insider Report for PFIZER INC (PFE)

Role: President R&D
Signature: Susan E. Grant, by power of atty., for Mikael Dolsten
Stock symbol: PFE
Transactions as of: Nov 7, 2022
Transactions value $: $2,627,260
Form type: 4
Date filed: 11/9/2022, 03:08 PM
Previous filing: May 12, 2022
Next filing: Feb 24, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PFE	Common Stock	Options Exercise	$1.54M	+50.9K	+14.94%	$30.17	392K	Nov 7, 2022	Direct	F1
transaction	PFE	Common Stock	Options Exercise	$1.09M	+28.2K	+7.19%	$38.71	420K	Nov 7, 2022	Direct	F1
holding	PFE	Common Stock						1.85K	Nov 7, 2022	By Rule 16b-3 Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PFE	Stock Appreciation Rights	Options Exercise	$0	-127K	-100%	$0.00^*	0	Nov 7, 2022	Common Stock	127K	$30.17	Direct
transaction	PFE	Stock Appreciation Rights	Options Exercise	$0	-133K	-100%	$0.00^*	0	Nov 7, 2022	Common Stock	133K	$38.71	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of stock units received upon the exercise and conversion of previously granted stock appreciation rights (SARs), calculated by taking the change in Pfizer common stock price (20 trading day average ending on the exercise date (Election Price of $45.07)) less the grant price of the SAR plus accumulated dividends from the grant date, times the number of SARs exercised. This value is divided by the Election Price to determine the number of stock units. The stock units and accumulated dividend units will be settled in Pfizer common stock on the SAR original settlement date, the seventh anniversary of grant.

Content

Represents the number of stock units received upon the exercise and conversion of previously granted stock appreciation rights (SARs), calculated by taking the change in Pfizer common stock price (20 trading day average ending on the exercise date (Election Price of $45.07)) less the grant price of the SAR plus accumulated dividends from the grant date, times the number of SARs exercised. This value is divided by the Election Price to determine the number of stock units. The stock units and accumulated dividend units will be settled in Pfizer common stock on the SAR original settlement date, the seventh anniversary of grant.